Why the study?
Despite the emerging prevalence of LV thrombus in dilated cardiomyopathy, clinical characteristics, management, and disease prognosis are poorly studied.
Does direct oral anticoagulants (DOACs) improve thrombus resolution and clinical outcomes compared to warfarin in patients with dilated cardiomyopathy and left ventricular thrombus?
Does direct oral anticoagulants (DOACs) improve thrombus resolution and clinical outcomes compared to warfarin in patients with dilated cardiomyopathy and left ventricular thrombus?
In patients with dilated cardiomyopathy and left ventricular thrombus, DOACs demonstrate comparable efficacy and safety to warfarin for thrombus resolution and clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Comparable outcomes with DOACs versus warfarin should not yet change practice; leaves open need for randomized trials in LV thrombus.
Huang et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: